Please sign in to follow a disease.
Down syndrome
MONDO:0008608Down syndrome is a chromosomal abnormality caused by the presence of a third (partial or total) copy of the chromosome 21 genetic material and that is characterized by variable intellectual disability, muscular hypotonia, and joint laxity, often associated with a characteristic facial dysmorphism and various anomalies such as cardiac, gastrointestinal, or endocrine defects.
Also known as: Down syndrome, Down syndrome, Isolated cases, Down's syndrome, leukemia, megakaryoblastic, with or without Down syndrome, somatic, trisomy 21 (Down syndrome), complete trisomy 21 syndrome, trisomy 21, trisomy 21 syndrome
137 clinical trials for this condition and its sub-types, 135 tagged with Down syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Down syndrome
-
Trisomy 21 9 trials · 10 incl. sub-types
2 sub-types
- Mosaic trisomy 21 1 trial
- Complete trisomy 21 0 trials
-
Translocation Down syndrome 2 trials
3 sub-types
-
Partial segmental duplication 1 trial
Most studied deeper sub-types
-
Early safety trial of ION269 for Alzheimer's in down syndrome ends after just one participant
Disease control Stopped earlyThis early-stage study tested a drug called ION269 in adults with Down syndrome who also showed signs of Alzheimer's disease. The goal was to check if the drug was safe and tolerable when injected into the spinal fluid. Only one person took part, and the study was stopped early, …
Phase 1 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Down syndrome hyperactivity drug trial stalls after just 3 kids enrolled
Symptom relief Stopped earlyThis study tested the drug guanfacine to see if it could reduce hyperactivity and impulsivity in children aged 6 to 12 with Down syndrome. The plan was to give the drug or a placebo for 8 weeks and measure behavior changes. However, the trial was stopped early after only 3 childr…
Phase 2 • Sponsor: Rachel G. Greenberg, MD, MB, MHS • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC